Maddi Langweil

Creating a Journey with the Unknown: A Dana-Farber Physician-Scientist Story   

by

What makes us humans lies in our genes. But even with all their power, they are remarkably vulnerable to errors.   But these potentially harmful errors are an opportunity for humankind to study and treat, as it has been for Dana-Farber’s physician-scientist Srinivas Viswanathan, MD, PhD.   “We have the ability to make an impact,” Viswanathan said. “There are so many unanswered questions in cancer biology still, especially in our understanding of rarer subtypes of kidney cancer.”   One of these subtypes — called translocation renal cell carcinoma (tRCC) — occurs when a gene quietly moves, fuses with another gene, and … Read more

Three Recent Dana-Farber Research Studies to Know About  

by

Every year, physician researchers at Dana-Farber Cancer Institute reveal new treatments, protocols, and outcomes that advance cancer research. At one of this year’s biggest cancer research conferences, the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, Dana-Farber researchers presented 22 studies in breast, lung, and bladder cancer.  Here are three of the most exciting advancements — several nearing U.S. Food and Drug Administration (FDA) approval — shared by our experts nearly 4,000 miles across the world.  An oral therapy for advanced breast cancer   Erica Mayer, MD, MPH, director … Read more

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally  

by

Cancer can make its way through the body by shapeshifting through even the narrowest places, like a skilled driver navigating traffic. It has a sly way of adapting to its environment by finding detours around every blockade clinicians place in its path.   A study from the lab of Nilay Sethi, MD, PhD, in Dana-Farber’s Center … Read more